Ipsen ends neu­ro­tox­in pact with Gal­der­ma af­ter ar­bi­tra­tion cas­es filed in in­ter­na­tion­al court

Ipsen has ter­mi­nat­ed a 2014 neu­ro­tox­in R&D deal with Gal­der­ma af­ter the part­ner start­ed two cas­es at the In­ter­na­tion­al Cham­ber of Com­merce against Ipsen, …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER